Steroids and rituximab to prevent myasthenia from spreading
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with ocular myasthenia (eye muscle weakness) within the last 6 months
- Your symptoms are limited to droopy eyelids or double vision, and have lasted at least 1 month
- You have never taken immune-suppressing drugs for this condition
- You do not have a thymoma, thyroid eye disease, or serious health problems like heart failure or active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.
Hear when a new Ocular Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.